RP-6306

Phase 2Small molecule

DDebiopharm International SA

RP-6306 is one of 36 small molecule programs targeting Uterine Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Uterine CancerActive, not recruiting

Breast CancerRecruiting

Uterine CancerPhase 1

Active, not recruiting

Breast CancerPhase 2

Recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Adenocard

Astellas

Preclinical

2 2

RP-6306

DDebiopharm International SA

Phase 2

1 3

Duragesic

CCephalon

Preclinical

1 4

Rilvegostomig

AstraZeneca

Preclinical

1 5

Tianeptine

Pfizer

Preclinical

1 6

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 7

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 8

4SCAR T Cells

SShenzhen Geno-Immune Medical Institute

Preclinical

1 9

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

1 10

Liposomal Irinotecan and Apatinib

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Breast Cancer

NCT05601440

Clinical

Trials by Indication[1]

Advanced Solid Tumors2 trials

Study of RP-6306 With FOLFIRI in Advanced Solid Tumors

Terminated·DDebiopharm International SA·Phase 1·NCT05147350·38 enrolled

Study of RP-6306 With Gemcitabine in Advanced Solid Tumors

Terminated·DDebiopharm International SA·Phase 1·NCT05147272·67 enrolled

Breast Cancer1 trial

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Recruiting·CCanadian Cancer Trials Group·Phase 2·NCT05601440·484 enrolled

Uterine Cancer1 trial

Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer

Active, not recruiting·UUniversity Health Network, Toronto·Phase 1·NCT06107868·6 enrolled

Advanced Cancer1 trial

RP-6306 in Patients With Advanced Cancer

Completed·CCanadian Cancer Trials Group·Phase 2·NCT05605509·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for RP-6306. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RP-6306 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RP-6306. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Debiopharm International SA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: DDebiopharm International SA

RP-6306

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Advanced Solid Tumors2 trials

Breast Cancer1 trial

Uterine Cancer1 trial

Advanced Cancer1 trial

References

Drug Info

Quick Facts

Related News